<DOC>
	<DOCNO>NCT00478231</DOCNO>
	<brief_summary>To collect safety tolerability data diverse patient population patient HIV/Aids , limit therapeutic option .</brief_summary>
	<brief_title>Multicenter , Safety Study Of Maraviroc</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Subjects limit approved treatment option available due resistance intolerance ; Subjects must fail achieve adequate virologic suppression current regimen HIV1 RNA â‰¥ 1000 copies/ml , screen . Have R5 HIV1 Screening verify Monogram Biosciences Trofile assay . Failed prior treatment CCR5 antagonist , ongoing CCR5 trial previously discontinue Maraviroc trial Potentially life threatening ( Grade 4 ) laboratory abnormality medical condition ( accord Division AIDS table grade severity adult adverse experience ) still investigation unless diagnosis establish felt affect risk/benefit assessment eventual interpretation safety result , base discussion investigator Pfizer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Multicenter</keyword>
	<keyword>Open Label</keyword>
	<keyword>Non-Comparative Safety Study Of Maraviroc</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>